Search

Search Bar
01/02/2024 Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.
Villarrubia, JE, Gordoa, TA, Mellado-González, B, Duran, I, Pinto, A, Sanchez, A, Pous, AF, Vazquez-Estevez, S, Puente, J, Grande, E, Climent, MA, Maroto-Rey, P, Perez-Gracia, JL, Aix, SP, Castellano, D, Gonzalez-Billalabeitia, E. Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(4_SUPPL)DOI:10.1200/JCO.2024.42.4_suppl.TPS238. PMID:. IF:41.900(Q1/1D).
20/01/2024 Nutritional impact and prognostic role of systemic inflammatory response index (SIRI) in advanced pancreatic cancer: PANTHEIA-Spanish Society of Medical Oncology (SEOM) study results.
Pacheco-Barcia, V, Méndez, AM, Carmona-Bayonas, A, Gallego, J, Franco, CF, Adeva, J, Cerdà, P, Cabezon-Gutierrez, L, Custodio-Cabello, S, Ghanem, I, Hernandez, I, Lamarca, A, Laquente, B, López-Alfonso, A, Lago, NM, Macarulla, T, Peiro, I, Visa, L, Jimenez-Fonseca, P, Muñoz, A. Nutritional impact and prognostic role of systemic inflammatory response index (SIRI) in advanced pancreatic cancer: PANTHEIA-Spanish Society of Medical Oncology (SEOM) study results.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(3_SUPPL)DOI:10.1200/JCO.2024.42.3_suppl.623. PMID:. IF:41.900(Q1/1D).
20/01/2024 Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300.
Modest, DP, Fakih, M, Salvatore, L, Esaki, T, Lopez-Bravo, DP, Taieb, J, Karamouzis, M, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Cremolini, C, Tran, Q, Chan, E, Chao, J, Majer, IM, Pietrantonio, F. Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(3_SUPPL)DOI:10.1200/JCO.2024.42.3_suppl.10. PMID:. IF:41.900(Q1/1D).
08/01/2024 Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
Contreras-Toledo, D, Jiménez-Fonseca, P, López, CL, Montes, AF, Muñoz, AML, Rivera, FV, Alonso, V, Alcaide, J, Salvà, F, Rúa, MC, Guillot, M, Carnicero, AM, Mate, RJ, García, SC, Martínez, EA, Astorga, BG, Fernandez-Diaz, AB, Villaroel, PG, Manrique, ACV, Sosa, MM, Alonso, B, Castiñeiras, AC, López, CC, Aparicio, J, Carmona-Bayonas, A. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?. BRITISH JOURNAL OF CANCER. 2024; 130(5)DOI:10.1038/s41416-023-02563-w. PMID:38191609. IF:6.800(Q1/2D).